Amryt Pharma plc [AMYT] vs UnitedHealth [UNH] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amryt Pharma plc wins in 3 metrics, UnitedHealth Group Incorporated wins in 10 metrics, with 2 ties. UnitedHealth Group Incorporated appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amryt Pharma plc UnitedHealth Group Incorporated Better
P/E Ratio (TTM) 39.73 26.81 UnitedHealth Group Incorporated
Price-to-Book Ratio 2.80 3.42 Amryt Pharma plc
Debt-to-Equity Ratio 164.32 73.98 UnitedHealth Group Incorporated
PEG Ratio -0.39 -0.27 UnitedHealth Group Incorporated
EV/EBITDA 0.00 17.29 Tie
Profit Margin (TTM) 52.32% 2.68% Amryt Pharma plc
Operating Margin (TTM) -0.86% 8.05% UnitedHealth Group Incorporated
EBITDA Margin (TTM) N/A 8.05% N/A
Return on Equity -94.18% 12.18% UnitedHealth Group Incorporated
Return on Assets (TTM) -2.32% 3.78% UnitedHealth Group Incorporated
Free Cash Flow (TTM) N/A $16.08B N/A
Dividend Yield N/A 3.84% N/A
1-Year Return N/A 30.30% N/A
Price-to-Sales Ratio (TTM) 4.24 0.72 UnitedHealth Group Incorporated
Enterprise Value $0 $371.09B UnitedHealth Group Incorporated
EV/Revenue Ratio 0.00 0.83 Tie
Gross Profit Margin (TTM) 44.86% 16.34% Amryt Pharma plc
Revenue per Share (TTM) $5 $496 UnitedHealth Group Incorporated
Earnings per Share (Diluted) $0.02 $13.24 UnitedHealth Group Incorporated
Beta (Stock Volatility) N/A 0.41 N/A
Short % of Float N/A 1.86% N/A

Amryt Pharma plc vs UnitedHealth Group Incorporated Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amryt Pharma plc0.00%0.00%0.00%0.00%0.00%0.00%
UnitedHealth Group Incorporated0.62%1.10%4.36%43.98%20.50%22.19%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amryt Pharma plcN/AN/AN/AN/AN/AN/A
UnitedHealth Group Incorporated30.30%-10.90%4.92%196.70%717.69%822.38%

Performance & Financial Health Analysis: Amryt Pharma plc vs UnitedHealth Group Incorporated

MetricAMYTUNH
Market Information
Market Cap iN/A$322.34B
Market Cap CategoryN/AMega cap
10 Day Avg. Volume i2,376,3859,626,040
90 Day Avg. Volume i1,458,1829,353,900
Last Close$14.70$411.04
52 Week Range$14.70 - $14.71$234.60 - $415.98
% from 52W High-0.07%-1.19%
All-Time High$14.71 (Jan 16, 2025)$630.73 (Nov 11, 2024)
% from All-Time High-0.07%-34.83%
Growth Metrics
Quarterly Revenue Growth-0.11%0.02%
Quarterly Earnings GrowthN/A0.00%
Financial Health
Profit Margin (TTM) i0.52%0.03%
Operating Margin (TTM) i-0.01%0.08%
Return on Equity (TTM) i-0.94%0.12%
Debt to Equity (MRQ) i164.3273.98
Cash & Liquidity
Book Value per Share (MRQ)$0.02$103.87
Cash per Share (MRQ)$1.30$34.32
Operating Cash Flow (TTM) i$-29,023,000$23.15B
Levered Free Cash Flow (TTM) i$-18,171,000$17.69B
Dividends
Last 12-Month Dividend Yield iN/A3.84%
Last 12-Month Dividend iN/A$10.94

Valuation & Enterprise Metrics Analysis: Amryt Pharma plc vs UnitedHealth Group Incorporated

MetricAMYT (Mar 31, 2025)UNH (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i39.7326.81
Forward P/E i-490.0017.17
PEG Ratio i-0.39-0.27
Price to Sales (TTM) i4.240.72
Price to Book (MRQ) i2.803.42
Market Capitalization
Market Capitalization i$942.77M$322.34B
Enterprise Value i$0$371.09B
Enterprise Value Metrics
Enterprise to Revenue i0.000.83
Enterprise to EBITDA i0.0017.29
Risk & Other Metrics
Beta iN/A0.41
Book Value per Share (MRQ) i$0.02$103.87

Financial Statements Comparison: Amryt Pharma plc vs UnitedHealth Group Incorporated

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMYTUNH (2025)
Revenue/Sales iN/A447.57B
Cost of Goods Sold iN/A364.65B
COGS % of Revenue i-81.5%
Gross Profit iN/A82.92B
Gross Margin i-18.5%
Research & Development iN/AN/A
Operating Income (EBIT) iN/A18.96B
Operating Margin i-4.2%
EBITDA iN/A23.33B
EBITDA Margin i-5.2%
Pre-Tax Income iN/A14.70B
Pre-Tax Income % of Revenue i-3.3%
Income Tax iN/A1.89B
Income Tax % of Revenue i-0.4%
Net Income (Profit) iN/A12.81B
Profit Margin i-2.9%

Balance Sheet & Liquidity Metrics

MetricAMYTUNH (2025)
Cash & Equivalents iN/A24.37B
Total Current Assets iN/A90.58B
Total Current Assets % of Revenue i-20.2%
Total Current Liabilities iN/A114.90B
Total Current Liabilities % of Revenue i-25.7%
Long-Term Debt iN/A72.32B
Long-Term Debt % of Revenue i-16.2%
Total Shareholders Equity iN/A101.70B
Retained Earnings iN/A95.60B
Retained Earnings % of Revenue i-21.4%
Property, Plant & Equipment iN/A0

Cash Flow Statement Comparison

MetricAMYTUNH (2025)
Operating Cash Flow iN/A13.61B
Operating Cash Flow % of Revenue i-3.0%
Capital Expenditures iN/A-3.62B
Free Cash Flow iN/A16.08B
FCF Margin i-3.6%
Debt Repayment iN/A-3.05B
Common Stock Repurchase iN/A-5.55B

Short Interest & Institutional Ownership Analysis

MetricAMYTUNH
Shares Short iN/A15.18M
Short Ratio iN/A1.68
Short % of Float iN/A1.86%
Shares Outstanding i64.13M905.84M
Float Shares iN/A902.31M
% Held by Insiders iN/A0.81%
% Held by Institutions iN/A83.96%
% Held by Public iN/A15.23%

Dividend Analysis & Yield Comparison: Amryt Pharma plc vs UnitedHealth Group Incorporated

MetricAMYTUNH
Last 12-Month Dividend iN/A$10.94
Last 12-Month Dividend Yield iN/A3.84%
3-Year Avg Annual Dividend iN/A$8.25
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$24.76
Ex-Dividend DateN/AMar 09, 2026